Study title: Open label, non-comparative study of Cefotaxime (300 mg/kg/day) plus vancomycin (60 mg/kg/day) combination as first line treatment of pneumococcal meningitis in children aged from 3 months to 18 years
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Bacterial Infections and Mycoses | |||||
Brands: | |||||
MAH holders: Please see report, Please see report | |||||
Assessment: | |||||
Active substance: CEFOTAXIME | |||||
ATC code: | |||||
Document link: Cefotaxime-Study 1.pdf | |||||
Document date: 2011-09-23 | |||||
Study number: FR/94/756/12 | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | Y | Y | Y |